Last updated: February 20, 2026
What is AMIDATE?
AMIDATE (methohexital sodium), marketed by Hospira (a Pfizer subsidiary), is an ultra-short-acting barbiturate used primarily for anesthesia induction and diagnostic procedures. It has a well-established profile in hospitals, outpatient clinics, and various anesthesia settings globally.
Market Overview and Demand Drivers
The global anesthesia drugs market was valued at approximately $6 billion in 2022, with a compound annual growth rate (CAGR) of 4.5% through 2028 [1]. AMIDATE’s segment accounts for a niche but stable portion mainly supported by hospitals and specialized care settings.
Key demand drivers involve:
- Rising global healthcare infrastructure and anesthesia procedures.
- Aging populations increasing procedural volume.
- Ongoing need for fast-acting anesthetic agents with predictable recovery profiles.
However, the market is facing challenges from newer sedation agents with improved safety profiles and ease of administration.
Competitive Landscape
The primary competitors include:
| Drug Name |
Market Share |
Administration Route |
Special Features |
| AMIDATE |
Estimated 15% |
Intravenous |
Rapid onset, short duration |
| Propofol |
~55% |
Intravenous |
Widely used, antiemetic properties |
| Etomidate |
~20% |
Intravenous |
Hemodynamic stability |
| Other agents |
10% |
Various |
Limited use due to side effects |
AMIDATE’s competitive edge lies in its rapid onset and short duration, suitable for brief procedures.
Patent and Regulatory Status
- Patent protection: Patents for methohexital expired globally by 2019, enabling generic production [2].
- Regulatory approvals: Approved by FDA (U.S.) since 1958; also approved in Europe, Japan, and other jurisdictions.
- Manufacturing arrangements: Currently supplied by Pfizer/Hospira; generic manufacturers can produce equivalents post-patent expiry.
Investment Fundamentals
Financial Position
- Market reliance on hospital procurement constrains pricing power.
- Margins depend heavily on manufacturing costs and reimbursement rates.
- The drug’s niche status shields it from direct competition with blockbuster agents like Propofol but limits sales volume.
Revenue Trends and Forecasts
- Current annual sales approximate $50–70 million globally.
- Future revenues depend on procedural volume growth and formulary preferences.
- Given the generic status, profit margins could decline due to price competition.
Cost Structure
- Manufacturing costs are relatively low for generics but involve regulatory compliance and Good Manufacturing Practices.
- Marketing expenses are minimal due to the niche and hospital procurement channels.
Risks and Opportunities
| Risks |
Opportunities |
| Market shrinkage due to safer alternatives |
Clinical guidelines favoring AMIDATE in specific cases |
| Price erosion post-patent expiry |
Growth in procedural volume in emerging markets |
| Regulatory shifts reducing usage |
Adoption in anesthesia protocols requiring rapid onset agents |
Regulatory and Reimbursement Environment
Reimbursement largely follows hospital-based procurement policies. Changes in healthcare policies or hospital formulary preferences could impact sales.
Strategic Outlook
From an investment perspective, AMIDATE's prospects hinge on:
- Maintaining relevance through clinical guideline inclusion.
- Capitalizing on procedural growth, especially in Asia-Pacific.
- Navigating patent expiration impacts through cost management and potential lifecycle extensions or line extensions.
Key Takeaways
- Market position: AMIDATE remains a niche but stable product within the anesthesia market.
- Competitive dynamics: Faces competition from Propofol and etomidate, with potential erosion post-patent expiry.
- Revenue outlook: Limited growth potential unless supported by procedural volume increases or clinical adoption.
- Risks: Market shifts towards newer agents, price competition, and regulatory changes.
- Opportunities: Growth in emerging markets and specialized clinical scenarios favoring rapid-onset agents.
FAQs
1. Is AMIDATE a high-growth investment candidate?
No. Its market is stable but mature with limited growth prospects post-patent expiry, mainly driven by procedural volumes.
2. How is the competitive landscape shifting?
Propofol’s dominance increases due to broad clinical acceptance; newer agents with reduced side effects may marginalize AMIDATE further.
3. What impact does patent expiry have on AMIDATE?
Patent expiry opens the market for generics, potentially leading to price erosion and reduced margins for branded formulations.
4. Are there regulatory advantages or risks?
The drug’s established regulatory approval minimizes risks; newly introduced safety concerns or restrictions could impact usage.
5. What regional growth opportunities exist?
Emerging markets with expanding healthcare infrastructure and anesthesia procedures provide growth opportunities, although price sensitivity is higher.
References
[1] MarketsandMarkets. (2022). Anesthesia drugs market report.
[2] U.S. Patent and Trademark Office. (2019). Patent expiry dates for methohexital sodium.
